Astrazeneca (AZN) Consolidated Net Income (2009 - 2026)

Astrazeneca has reported Consolidated Net Income for 18 years, with the latest figure at $3.1 billion in Q2 2026.

• On a quarterly basis, Consolidated Net Income fell 18.81% year-over-year to $3.1 billion in Q2 2026; TTM through Jun 2026 was $25.9 billion, a 120.49% increase from a year earlier, with the FY2025 full-year figure at $14.6 billion, up 40.91% from the prior year.
• Consolidated Net Income was $3.1 billion for Q2 2026 at Astrazeneca, down from $4.7 billion in the prior quarter.
• The five-year high for Consolidated Net Income was $14.1 billion in Q4 2025, with the low at $134.0 million in Q2 2022.
• Average Consolidated Net Income over 5 years is $3.3 billion, with a median of $2.8 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Consolidated Net Income plunged 86.3% in 2022, then surged 1658.21% in 2023.
• Over 5 years, Consolidated Net Income stood at $654.0 million in 2022, then soared by 970.64% to $7.0 billion in 2023, then slumped by 73.84% to $1.8 billion in 2024, then surged by 669.87% to $14.1 billion in 2025, then plunged by 78.09% to $3.1 billion in 2026.
• The last three Consolidated Net Income figures came in at $3.1 billion (Q2 2026), $4.7 billion (Q1 2026), and $14.1 billion (Q4 2025), per Business Quant data.